Literature DB >> 15917531

Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections.

Patricia Komp Lindgren1, Linda L Marcusson, Dorthe Sandvang, Niels Frimodt-Møller, Diarmaid Hughes.   

Abstract

Resistance to fluoroquinolones in urinary tract infection (UTIs) caused by Escherichia coli is associated with multiple mutations, typically those that alter DNA gyrase and DNA topoisomerase IV and those that regulate AcrAB-TolC-mediated efflux. We asked whether a fitness cost is associated with the accumulation of these multiple mutations. Mutants of the susceptible E. coli UTI isolate Nu14 were selected through three to five successive steps with norfloxacin. Each selection was performed with the MIC of the selected strain. After each selection the MIC was measured; and the regions of gyrA, gyrB, parC, and parE, previously associated with resistance mutations, and all of marOR and acrR were sequenced. The first selection step yielded mutations in gyrA, gyrB, and marOR. Subsequent selection steps yielded mutations in gyrA, parE, and marOR but not in gyrB, parC, or acrR. Resistance-associated mutations were identified in almost all isolates after selection steps 1 and 2 but in less than 50% of isolates after subsequent selection steps. Selected strains were competed in vitro, in urine, and in a mouse UTI infection model against the starting strain, Nu14. First-step mutations were not associated with significant fitness costs. However, the accumulation of three or more resistance-associated mutations was usually associated with a large reduction in biological fitness, both in vitro and in vivo. Interestingly, in some lineages a partial restoration of fitness was associated with the accumulation of additional mutations in late selection steps. We suggest that the relative biological costs of multiple mutations may influence the evolution of E. coli strains that develop resistance to fluoroquinolones.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15917531      PMCID: PMC1140522          DOI: 10.1128/AAC.49.6.2343-2351.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  40 in total

Review 1.  The mar regulon: multiple resistance to antibiotics and other toxic chemicals.

Authors:  M N Alekshun; S B Levy
Journal:  Trends Microbiol       Date:  1999-10       Impact factor: 17.079

2.  Effects of environment on compensatory mutations to ameliorate costs of antibiotic resistance.

Authors:  J Björkman; I Nagaev; O G Berg; D Hughes; D I Andersson
Journal:  Science       Date:  2000-02-25       Impact factor: 47.728

3.  Virulence genotype and phylogenetic origin in relation to antibiotic resistance profile among Escherichia coli urine sample isolates from Israeli women with acute uncomplicated cystitis.

Authors:  James R Johnson; Michael A Kuskowski; Timothy T O'bryan; Raul Colodner; Raul Raz
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

4.  Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.

Authors:  F J Schmitz; M E Jones; B Hofmann; B Hansen; S Scheuring; M Lückefahr; A Fluit; J Verhoef; U Hadding; H P Heinz; K Köhrer
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

5.  Molecular analysis of fluoroquinolone-resistance in Escherichia coli on the aspect of gyrase and multiple antibiotic resistance (mar) genes.

Authors:  Y H Park; J H Yoo; D H Huh; Y K Cho; J H Choi; W S Shin
Journal:  Yonsei Med J       Date:  1998-12       Impact factor: 2.759

6.  Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli.

Authors:  S Langermann; R Möllby; J E Burlein; S R Palaszynski; C G Auguste; A DeFusco; R Strouse; M A Schenerman; S J Hultgren; J S Pinkner; J Winberg; L Guldevall; M Söderhäll; K Ishikawa; S Normark; S Koenig
Journal:  J Infect Dis       Date:  2000-02       Impact factor: 5.226

7.  Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli.

Authors:  W V Kern; M Oethinger; A S Jellen-Ritter; S B Levy
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

8.  Development of a long-term ascending urinary tract infection mouse model for antibiotic treatment studies.

Authors:  H Hvidberg; C Struve; K A Krogfelt; N Christensen; S N Rasmussen; N Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2000-01       Impact factor: 5.191

9.  DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae.

Authors:  X S Pan; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

10.  Characterization of fluoroquinolone-resistant mutants of escherichia coli selected in vitro.

Authors:  P Heisig; R Tschorny
Journal:  Antimicrob Agents Chemother       Date:  1994-06       Impact factor: 5.191

View more
  50 in total

1.  Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli.

Authors:  Renu Singh; Michelle C Swick; Kimberly R Ledesma; Zhen Yang; Ming Hu; Lynn Zechiedrich; Vincent H Tam
Journal:  Antimicrob Agents Chemother       Date:  2012-01-09       Impact factor: 5.191

2.  Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.

Authors:  Daniel E Rozen; Lesley McGee; Bruce R Levin; Keith P Klugman
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

3.  Resistance and Virulence Mechanisms of Escherichia coli Selected by Enrofloxacin in Chicken.

Authors:  Jun Li; Haihong Hao; Menghong Dai; Heying Zhang; Jianan Ning; Guyue Cheng; Muhammad Abu Bakr Shabbir; Abdul Sajid; Zonghui Yuan
Journal:  Antimicrob Agents Chemother       Date:  2019-04-25       Impact factor: 5.191

4.  The asymptomatic bacteriuria Escherichia coli strain 83972 outcompetes uropathogenic E. coli strains in human urine.

Authors:  Viktoria Roos; Glen C Ulett; Mark A Schembri; Per Klemm
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

Review 5.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

Review 6.  Antibiotic resistance and its cost: is it possible to reverse resistance?

Authors:  Dan I Andersson; Diarmaid Hughes
Journal:  Nat Rev Microbiol       Date:  2010-03-08       Impact factor: 60.633

Review 7.  Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.

Authors:  Diarmaid Hughes; Dan I Andersson
Journal:  Nat Rev Genet       Date:  2015-07-07       Impact factor: 53.242

8.  Interplay in the selection of fluoroquinolone resistance and bacterial fitness.

Authors:  Linda L Marcusson; Niels Frimodt-Møller; Diarmaid Hughes
Journal:  PLoS Pathog       Date:  2009-08-07       Impact factor: 6.823

9.  Genome-scale identification method applied to find cryptic aminoglycoside resistance genes in Pseudomonas aeruginosa.

Authors:  Julie M Struble; Ryan T Gill
Journal:  PLoS One       Date:  2009-11-11       Impact factor: 3.240

10.  Antimicrobial resistances do not affect colonization parameters of intestinal E. coli in a small piglet group.

Authors:  Peter Schierack; Kristina Kadlec; Sebastian Guenther; Matthias Filter; Stefan Schwarz; Christa Ewers; Lothar H Wieler
Journal:  Gut Pathog       Date:  2009-10-08       Impact factor: 4.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.